Lupin and TB Alliance have entered into a strategic collaboration to advance the clinical development and commercialisation of Telacebec, an investigational drug for the treatment of tuberculosis and other mycobacterial diseases, including leprosy and Buruli ulcer.
The partnership between Lupin and TB Alliance will enable both organizations to facilitate the development of Telacebec and wider access for patients. TB Alliance will remain responsible for clinical development efforts while Lupin will apply its global manufacturing, regulatory and supply chain skills to aid in multi-market distribution.
“This collaboration with TB Alliance underscores Lupin’s enduring commitment to improving patient outcomes in areas of significant unmet medical need,” said Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin. “By leveraging our manufacturing scale and global distribution capabilities alongside TB Alliance’s deep expertise in drug development, we aim to enable timely and equitable access to Telacebec and contribute meaningfully to the global fight against tuberculosis, leprosy, and Buruli ulcer.”
Telacebec, previously known as Q203, is currently being developed as a potential new medicine to treat people with mycobacterial infections. There will be a focus on swift and responsible development and continued access.
“Telacebec represents the kind of scientific innovation that has the potential to transform treatment for diseases that have long been neglected,” said Mel Spigelman, MD, President and CEO, TB Alliance. “By partnering with Lupin, we are combining deep scientific expertise with global Chemistry, Manufacturing and Controls and access capabilities to help move this promising compound forward as quickly and responsibly as possible, with the ultimate goal of delivering better treatment options to people affected by tuberculosis, leprosy, and Buruli ulcer around the world.”
